Chris Mirabelli

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^

Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

Part of Procter & Gamble Co., SmithKline & French SpA is a pharmaceutical concern. SmithKline & French was acquired by Procter & Gamble Co. from Smithkline Beecham Plc on September 29, 1993.

Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA.

Visionary Therapeutics Corp. develops ocular therapeutics for eye diseases. The company was founded by Steve Hutcherson and is headquartered in Richmond, VA

Anexon, Inc. develops therapeutics for cardiovascular diseases. The firm develops an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was founded in 2006 by Robert D. Simari and is headquartered in Cambridge, MA.

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services.

Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

The Fredonia College Foundation is a non-profit organization that supports the State University of New York at Fredonia by providing financial assistance to students, faculty, and staff. The foundation is based in Fredonia, NY. The foundation offers scholarships, grants, and other forms of aid to help students achieve their academic goals. It also supports research and other initiatives that enhance the educational experience at the university.